Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
Michael Friedländer(Prince of Wales Hospital), Éric Pujade-Lauraine(Eau de Paris (France)), Felix Hilpert(Krankenhaus Jerusalem), Val Gebski(The University of Sydney), Tomasz Huzarski(International Hereditary Cancer Center), Andrew R. Clamp, Salutari, Florence Joly(Centre François Baclesse), Jacob Korach(Tel Aviv University), Liat Vidal(Rabin Medical Center), Manuel Rodrigues(Inserm), Keita Tamura, Emma Gibbs(The University of Sydney), Daniel Eek(AstraZeneca (Sweden)), Ralph Bloomfield(AstraZeneca (United Kingdom)), C. Scott, Maria Ornella Nicoletto, Lari Wenzel(University of California, Irvine), R. Penson(Southampton Hospital), Diane Provencher(Centre Hospitalier de l’Université de Montréal)
Unknown
January 1, 2017
Cited by 1
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k